Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP + Lenalidomide in High Risk DLBCL
NCT04214626Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Henan Cancer Hospital. Started Jan 2020; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04214626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214626.